Astaxanthin Synthetase

Abstract: The present invention is directed to genetic materials useful for the preparation of astaxanthin from beta-carotene, such as polypeptides having astaxanthin synthase activity, DNA fragments coding for astaxanthin synthase, recombinant organisms and the like. Those novel genetic materials may be originated from Phaffia rhodozyma. The present invention also provides a process for the production of astaxanthin.

Description: The present invention relates to recombinant production of carotenoids and biological materials useful therefor. Phaffia rhodozyma (P. rhodozyma) is a carotenogenic yeast strain which produces astaxanthin. Astaxanthin is distributed in a wide variety of organisms such as animal (birds such as flamingo and scarlet ibis, and fish such as rainbow trout and salmon), algae and microorganisms. It is also recognized that astaxanthin has a strong antioxidation property against oxygen radical, which is expected to apply for pharmaceutical usage to protect living cells against some diseases such as a cancer. Moreover, industrial need for astaxanthin as a coloring reagent is increasing, especially in the industry of farmed fish like salmon, because astaxanthin imparts distinctive orange-red coloration to the animals and contributes to consumer appeal in the marketplace. P. rhodozyma is known as a carotenogenic yeast strain which produces astaxanthin. Different from the other carotenogenic yeast, Rhodotorula species, P. rhodozyma can ferment some sugars such as D-glucose. This is an important feature from a viewpoint of industrial application. In a recent taxonomic study, a sexual cycle of P. rhodozyma was revealed and its telemorphic state was designated under the name of Xanthophyllomyces dendrorhous (W. I. Golubev; Yeast 11, 101 - 110, 1995). Some strain improvement studies to obtain hyper producers of astaxanthin from P. rhodozyma have been conducted, but such efforts have been restricted to employ the method of conventional mutagenesis and protoplast fusion in this decade. Recently, Wery et al. developed a host vector system using P. rhodozyma in which a non-replicable plasmid was used to be integrated in multicopies into the genome of the ribosomal DNA of P. rhodozyma (Wery et al., Gene, 184, 89-97, 1997). Verdoes et al. reported more improved vectors to obtain a transformant of P. rhodozyma as well as its three carotenogenic genes which code for the enzymes that catalyzes the reactions from geranylgeranyl pyrophosphate to beta-carotene (WO 97/23633). A specific biosynthetic pathway for carotenogenesis branches from general isoprenoid pathway at the point of important intermediate, farnesyl pyrophosphate (FPP) (FIG.1). FPP and IPP are condensed by geranylgeranyl pyrophosphate (GGPP) synthase which is coded by crtE in P. rhodozyma to produce GGPP. GGPP is then converted to beta-carotene by the sequential reaction of an enzyme functioning doubly as phytoene synthase and lycopene cyclase which is coded by crtBY and phytoene desaturase coded by crtI. In bacteria, enzymes and genes which are involved in xanthophyll formation have been isolated and characterized in detail. beta-Carotene hydroxylase which is coded by crtZ is involved in the two steps of hydroxylation for beta-ionone-ring of beta-carotene at both of the ends. The crtZ gene was cloned from wide variety of organisms such as Erwinia uredovora (Misawa et al., J. Bacteriol., 172, 6704-6712, 1990), Flavobactor species (L. Pasamontes et al., 185 (1), 35-41, 1997) and Agrobacterium aurantiacum (Misawa et al., J. Bacteriol., 177 (22), 6575-6584, 1995). beta-Carotene ketolase which is coded by crtW catalyzes the two steps of introduction of oxo-group into beta-ionone -ring of beta-carotene at both of the ends. Kajiwara et al. cloned and sequenced bkt gene corresponding to crtW in eubacteria from Haematococcus bluvialis (Kajiwara et al., P. Mol. Biol., 29, 343-352, 1995). Harker et al. also cloned and sequenced crtO gene corresponding to crtW in eubacteria from Synechococcus PCC7942 (Harker et al., FEBS Letters, 404, 129-134, 1997). Both enzymes the hydroxylase and the ketolase have wide substrate specificity and this ensures the formation of wide variety of xanthophylls in case that both of the enzymes react at the same time depending on the reaction condition. (FIG.1) As described above, all the genes which were involved in the formation of beta-carotene from FPP were isolated but the enzymes and genes which would be involved in the last step of xanthophyll formation from beta-carotene have not been identified on the protein and DNA level in P. rhodozyma. Although Johnson et al. (Crit. Rev. Biotechnol, 11 (4), 297 - 326, 191) proposed the existence of two independent pathways for astaxanthin formation by assuming that some of the xanthophyll compounds isolated by them would be intermediates of astaxanthin biosynthesis, such two independent pathways could not be proven because enzymes and genes which are involved in such pathways could not be isolated. Furthermore, it can not be excluded that these xanthophyll compounds could have been resulted from an experimental artifact in the isolation step of these compounds. Failure to isolate a mutant from P. rhodozyma which accumulates intermediates on the biosynthetic pathway from beta-carotene to astaxanthin made it difficult to clarify the biosynthetic pathway from beta-carotene to astaxanthin. This invention relates to a gene and enzyme which is involved in the last step of the astaxanthin biosynthesis from beta-carotene to astaxanthin. The present invention, provides an isolated DNA, specifically cDNA comprising a nucleotide sequence coding for astaxanthin synthase which is involved in the reaction from beta-carotene to astaxanthin in P. rhodozyma, like the AST gene. In a preferred embodiment, the cloned DNA fragment can be characterized in that (a) the said nucleotide sequence codes for the said enzyme having an amino acid sequence described in SEQ ID NO: 1, or (b) the said nucleotide sequence codes for a variant of the said enzyme selected from (i) an allelic variant or (ii) an enzyme having one or more amino acid addition, insertion, deletion and/or substitution and having the stated enzyme activity. In another preferred embodiment, the isolated cDNA fragment can be derived from a gene of Phaffia rhodozyma and is selected from: (i) a cDNA sequence represented by SEQ ID NO: 2; (ii) an isocoding or an allelic variant for the cDNA sequence represented by SEQ ID NO: 2; and (iii) a derivative of a cDNA sequence represented by SEQ ID NO: 2 with addition, insertion, deletion and/or substitution of one or more nucleotide(s), and coding for a polypeptide having the said enzyme activity. In another preferred embodiment the present invention is directed to the isolated cDNA as described above, which is characterized in that the said nucleotide sequence is: (i) a nucleotide sequence represented in SEQ ID NO: 2; (ii) a nucleotide sequence which, because of the degeneracy of the genetic code, encodes an astaxanthin synthase having the same amino acid sequence as that encoded by the nucleotide sequence (i); and (iii) a nucleotide sequence which hybridizes to the complement of the nucleotide sequence from i) or ii) under standard hybridizing conditions. In still another preferred embodiment, the isolated genomic DNA fragment can be derived from a gene of Phaffia rhodozyma and is selected from: (i) a genomic DNA sequence represented by SEQ ID NO: 3; (ii) an isocoding or an allelic variant for the genomic DNA sequence represented by SEQ ID NO: 3; and (iii) a derivative of a genomic DNA sequence represented by SEQ ID NO: 3 with addition, insertion, deletion and/or substitution of one or more nucleotide(s), and coding for a polypeptide having the said enzyme activity. In another preferred embodiment the present invention is directed to the isolated genomic DNA as described above, which is characterized in that the said nucleotide sequence is: (i) a nucleotide sequence represented in SEQ ID NO: 3; (ii) a nucleotide sequence which, because of the degeneracy of the genetic code, encodes an astaxanthin synthase having the same amino acid sequence as that encoded by the nucleotide sequence (i); and (iii) a nucleotide sequence which hybridizes to the complement of the nucleotide sequence from i) or ii) under standard hybridizing conditions. Another aspect of the present invention, provides a recombinant polypeptide having an astaxanthin synthase activity involved in the reaction from beta-carotene to astaxanthin in P. rhodozyma which is obtainable by the expression of the cloned DNA fragment as set forth above. A preferred embodiment of the recombinant polypeptide of the present invention is characterized in that (a) the said polypeptide has an amino acid sequence as described in SEQ ID NO: 1, or (b) the said polypeptide is a variant of the peptide defined in (a) which is selected from (i) an allelic variant or (ii) an enzyme having one or more amino acid addition, insertion, deletion and/or substitution and having the stated enzyme activity. Therefore the present invention is also directed to variants of the polypeptides of the present case. Such variants are defined on the basis of the amino acid sequence of the present invention by addition, insertion, deletion and/or substitution of one or more amino acid residues of such sequences wherein such derivatives still have the same type of enzymatic activity as the corresponding polypeptides of the present invention or they are the result of the well known phenomenon of allelic variation. Such activities can be measured by any assays known in the art or specifically described herein. Such variants can be made either by chemical peptide synthesis known in the art or by recombinant means on the basis of the DNA sequences as disclosed herein by methods known in the state of the art, such as, e.g. that disclosed by Sambrook et al. (Molecular Cloning, Cold Spring Harbour Laboratory Press, New York, USA, second edition 1989). Amino acid exchanges in proteins and peptides which do not generally alter the activity of such molecules are known in the state of the art and are described, for example, by H. Neurath and R.L. Hill in "The Proteins" (Academix Press, New York, 1979, see especially Figure 6, page 14). The most commonly occurring exchanges are: Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/thr, Ser/Asn, Ala/Val, Ser/Gly, Thy/Phe, Ala/Pro, Lys/Art. Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, Asp/Gly as well as the reverse. Furthermore the present invention is not only directed to the DNA sequences as disclosed e.g., in the sequence listing as well as their complementary strands, but also to those which include these sequences, DNA sequences which hybridize under Standard Conditions with such sequences or fragments thereof and DNA sequences, which because of the degeneration of the genetic code, do not hybridize under Standard Conditions with such sequences but which code for polypeptides having exactly the same amino acid sequence. "Standard Conditions" for hybridization mean in this context the conditions which are generally used by a man skilled in the art to detect specific hybridization signals and which are described, e.g. by Sambrook et al., (s.a.) or preferably so-called stringent hybridization and non-stringent washing conditions, or more preferably so-called stringent hybridization and stringent washing conditions a man skilled in the art is familiar with and which are described, e.g., in Sambrook et al. (s.a) or more preferably so-called medium stringent conditions, e.g. using the DIG (digoxigenin) labeling kit and luminescent detection kit of Boehringer Mannheim (Mannheim, Germany) following the protocol given by the manufacturer and using as the hybridization solution: formamide (WAKO, Osaka, Japan) 50% (V/V) 5 x SSC blocking reagent (Boehringer) 2% (W/V) N-lauroylsarcosine 0.1% (W/V) SDS 0.3% (W/V) at a temperature of 42°C over night and subsequently washing and detection as indicated by the manufacturer. DNA sequences which are derived from the DNA sequences of the present invention either because they hybridize with such DNA sequences (see above) or can be constructed by the polymerase chain reaction by using primers designed on the basis of such DNA sequences can be prepared either as indicated namely by the PCR reaction, or by site directed mutagenesis [see e.g., Smith, Ann. Rev. Genet. 19, 423 (1985)] or synthetically as described, e.g., in EP 747 483 or by the usual methods of Molecular Cloning as described, e.g., in Sambrook et al. (s.a.). The present invention is also directed to a vector or plasmid comprising a DNA as described above and a host cell transformed or transfected by a DNA as described above or a vector or plasmid as indicated above. The present invention also provides a recombinant organism which is obtainable by the transformation of a host using a recombinant DNA carrying the DNA as mentioned above. The present invention also relates to a method for producing an enzymatic polypeptide capable of catalyzing the reaction from beta-carotene to astaxanthin, which comprises culturing a recombinant organism described above under the condition conductive to the production of said enzymatic polypeptide. In a further aspect the present invention provides a method for the production of astaxanthin which comprises introducing one or more of the DNA described above into an appropriate host organism and cultivating this transformed organism under the conditions conductive to the production of astaxanthin. The enzymatic polypeptide of the present invention will be also useful for a method for the production of astaxanthin, which method comprises contacting beta-carotene with the recombinant polypeptide having an astaxanthin synthase activity involved in the reaction from beta-carotene to astaxanthin as set forth above in the presence of an appropriate electron donor in an appropriate reaction mixture containing an appropriate reconstituted membrane. In this method, said recombinant polypeptide may be present in the form of a reconstituted membrane which is prepared from biological membranes like microsomes or mitochondrial membranes. The recombinant polypeptide may be also present in the form of a reconstituted artificial membrane, like liposomes. The electron donor like cytochrome P450 reductase is an appropriate electron donor which can reduce a reaction center of the enzyme of the present invention. The following drawings are included to further illustrate the present invention together with the detailed description given below. FIG. 1 shows the biosynthetic pathway from acetyl-CoA to astaxanthin in P. rhodozyma. FIG. 2 shows a restriction map of the plasmid pR16 which harbors a partial genomic AST gene . In general, there are a number of methods to clone a gene coding for biosynthetic enzymes. For example, degenerate PCR can be used. Degenerate PCR is a method to clone a gene of interest which has high homology of its encoded amino acid sequence to the one of a known enzyme from other species which has the same or similar function. A degenerate primer, which is used as a set of primers in degenerate PCR, was designed by a reverse translation of the amino acid sequence to corresponding nucleotides ("degenerated"). In such a degenerate primer, a mixed primer which consists any of A, C, G or T, or a primer containing inosine at an ambiguity code is generally used. After cloning of a partial fragment of the gene of interest the genetic fragment containing the entire gene can be screened by using the cloned and labeled partial DNA fragment as a probe. In the case of cloning a gene encoding an enzyme whose activity can be measured by an enzymatic assay, purification of such an enzyme by monitoring enzyme activity and determination of its amino acid sequence for the enzyme is a good method. An amino acid sequence thus obtained is easily translated in reverse into the corresponding nucleotide sequence(s). A DNA fragment which has the corresponding nucleotide sequence can be synthesized in vitro with a DNA synthesizer and labeled for direct usage as a hybridization probe. An alternative way to obtain a hybridization probe is the degenerate PCR method using the amino acid sequence information. To clone a gene whose function can not be characterized enzymatically, a method called shot-gun screening has been employed as a conventional cloning method. This method comprises the isolation of a mutant strain which lacks the specific gene coding for any of the biosynthetic enzymes of interest, [and the transformation of the mutant strain by the DNA prepared from the organism that has an intact gene which corresponds to the gene as such mutated. For an isolation of such a mutant, conventional mutagenesis is often used. Confirmation of the acquired phenotype which is the same as that of the parent strain can be performed by examination of its auxotrophy and the like. In the case that the donor DNA contains the gene which corresponds to the mutated gene in the mutant strain, the transformant by such a gene acquired the same phenotype as the parent strain as a result of genetic complementation. As a vector, any form of vectors whether they can replicate or not in the cloning host, can be used for shot gun cloning. For the usage of a replicative vector, the capability of complementation is a requisite and it is not necessary that such a vector contains a homologous sequence to the genome of the recipient. In the case of using a non-replicative vector, it is necessary that such a vector contains a homologous sequence to the genome of the host to make a recombination between donor and recipient DNAs. For the cloning of the DNAs of the present invention the method called "color complementation" can be employed. Non carotenogenic organisms, such as Escherichia coli can acquire the carotenogenic ability as a result of transformation by carotenogenic genes which could be cloned from carotenogenic organisms such as Erwinia uredovora, Erwinia herbicola and the like. E. coli harboring crtE, crtB, crtI and crtY can produce beta-carotene and color the cells in yellow. Exploiting such a characteristics, numbers of carotenogenic genes have been cloned from various carotenogenic organisms such as bacteria and plants. For example, to clone the crtY gene coding for lycopene cyclase, E. coli harboring crtE, crtB and crtI on the compatible vector against pUC vector is prepared as a transformation host. Such a host turns red which shows accumulation of lycopene. Next, a cDNA or genomic library from carotenogenic organisms can be constructed using the pUC vector. If the gene corresponding to crtY in the donor carotenogenic organism is present in the transformed plasmid, genetic complementation would occur and E. coli would turn yellow which would show the acquisition of the ability to produce beta-carotene. In fact, crtE, crtBY and crtI gene were cloned from P. rhodozyma by this method (Verdoes et al., WO97/23633). Regarding the cloning of the gene which is involved in the reaction from beta-carotene to astaxanthin, Kajiwara et al. constructed a cDNA expression library from P. rhodozyma in the host E. coli harboring crtE, crtB, crtI and crtY genes from E. uredovora (Kajiwara et al., WO 96/28545, 1996). In such a cloning system, a gene which is involved in the reaction from beta-carotene to astaxanthin could be theoretically cloned from P. rhodozyma by judging red pigmentation which shows the accumulation of canthaxanthin or astaxanthin. However, such a gene has not been reported so far. Many researchers speculate about the possibility that membrane-bound carotenogenic enzymes would form an enzyme complex. In such a model, the affinity among carotenogenic enzymes would be necessary for efficient carotenogenesis. Based on such an assumption, this color complementation method is not suitable to clone the enzyme involved in the last step of astaxanthin biosynthesis, namely the one from beta-carotene to astaxanthin, because exogeneous enzymes might not have affinity to the Phaffia's carotenogenic enzyme in the sequential reaction of the carotenogenesis. In this invention, P. rhodozyma ATCC96815 which has been redeposited as a Budapest Treaty deposit at the American Type Culture Colleciton (ATCC) under accession number 74486 on February 18, 1999 and which is blocked for the reaction from beta-carotene to astaxanthin was used as a transformation host (Schroeder, W.A. and Johnson, E.A., J. Ind. Microbiol. 14 , 502-507, 1995). Transformation of this mutant by the genomic library prepared from the chromosome of a wild type strain of P. rhodozyma ATCC96594 which has also been redeposited as a Budapest Treaty deposit at the American Type Culture Collection (ATCC) under accession number 74438 on April 8, 1998 was used to isolate a clone which produces astaxanthin. In the present invention, such genetic fragment complementing the reaction from beta-carotene to astaxanthin in P. rhodozyma was isolated and its nucleotide sequence was determined. Such a gene / DNA of the present invention can be used for overproduction of astaxanthin through a gene dosage effect using gene amplification or promoter modification other than complementation of blocked mutation. In this invention, the point mutation of the P. rhodozyma ATCC96815 strain which rendered beta-carotene production to P. rhodozyma wild type strain was determined. From the sequencing result, it was suggested that the base change at the splicing sequence of the eigth intron of AST gene cause such a phenotype of specific beta-carotene accumulation through the improper splicing of mRNA. RT-PCR analysis detected the improper spliced product for AST gene and strongly supported the identification of the mutation point. This invention also provides the recombinant AST gene which can be expressed in different host organisms such as E. coli. In this invention, such recombinant AST gene was expressed in E. coli and it was confirmed that the AST gene encoded protein product size corresponded to the deduced molecular weight. Biological production of astaxanthin can be realized by using the novel AST gene and such recombinant DNA techniques. According to the present invention, the gene coding for the enzyme which is involved in the last step of astaxanthin biosynthesis was cloned from a cDNA library of P. rhodozyma, and their nucleotide sequence was determined. Furthermore, a part of genomic DNA including promoter and terminator was cloned and can be used for a cloning of its entire gene including the promoter and terminator region. There are several strategies to enhance the desired enzymatic activity of the protein of interest by using its DNA sequence. One strategy is to use the gene itself in its native form. The simplest approach is to amplify the genomic sequence including its regulatory sequences such as the promoter and the terminator. This can be done by cloning of the genomic fragment coding for the enzyme of interest into an appropriate vector with a selectable marker which functions in P. rhodozyma. A drug resistance gene coding for an enzyme that enables the host to survive in the presence of a toxic antibiotic is often used as a selectable marker. The G418 resistance gene harbored in pGB-Ph9 (Wery et al., Gene, 184, 89-97, 1997) is an example of such a vector construction. As a vector, two types of vectors can be commonly used. One of these types is an integration vector which does not have an autonomous replicating sequence. The plasmid pGB-Ph9 is an example of this type of vectors. Because such a vector does not have an autonomous replicating sequence, the above vector cannot replicate by itself and can be present only in an integrated form on the chromosome of the host as a result of a single-crossing recombination using the homologous sequence between a vector and the chromosome. By increasing the concentration of the corresponding drug in the selection medium, the strain in which the integrated gene is amplified on the chromosome can only survive. Another type of vector is a replicable vector which has an autonomous replicating sequence. Such a vector can exist in a multicopy state. In this type of vector, a nutrition complementation maker can be also used in the host which has an appropriate auxotrophy marker. The P. rhodozyma ATCC24221 strain which requires cytidine for its growth is one example of such an auxotroph. By using a CTP synthetase as a donor DNA for ATCC24221, a host vector system using a nutrition complementation can be established. Another strategy to overexpress an enzyme of interest is the placement of the gene of interest under a strong promoter. In such a strategy, the gene of interest must not necessarily be in a multicopy state. Furthermore, a promoter whose promoter activity is induced in an appropriate growth phase and an appropriate timing of cultivation can be also used. Production of astaxanthin accelerates in the late phase of the growth, such as the production phase of a secondary metabolite. For example, by placing carotenogenic genes under the control of a vegetative promoter, the gene expression of these genes could be induced in the exponential growth phase and the production of astaxanthin can become associated to the growth of the production strain. In this invention, promoter and terminator fragment for triose phosphate isomerase (TPI) gene was cloned from P. rhodozyma as one example of such constitutive promoter and terminator. Moreover, a restoration of astaxanthin production was confirmed in the transformants in which AST gene was expressed on the different locus (AMY locus which contains the amylase gene) on the chromosome of beta-carotene producing P. rhodozyma ATCC96815 driven by constitutive promoter and terminator derived from TPI gene. Still another strategy to overexpress enzymes of interest is mutation in its regulatory elements. For this purpose, a kind of reporter gene, such as the beta-galactosidase gene, luciferase gene, a gene coding for a green fluorescent protein, and the like is inserted between the promoter and the terminator sequence of the gene of interest so that all the parts including promoter, terminator and the reporter gene are fused and function together. A transformed P. rhodozyma in which said reporter gene is introduced on the chromosome or on the vector can be mutagenized in vivo to induce a mutation within the promoter region of the gene of interest. The mutation can be monitored by detecting the change of the activity coded for by the reporter gene. If the mutation occurs in a cis element of the gene, the mutation point would be determined by the rescue of the mutagenized gene and sequencing. This mutation can then be introduced to the promoter region on the chromosome by the recombination between the native and the mutated promotor sequence. In the same way a mutation in the gene which codes for a trans-acting factor can be made. A mutation can be also induced by an in vitro mutagenesis of a cis element in the promoter region. In this approach, a gene cassette, containing a reporter gene which is fused to a promoter region derived from a gene of interest at its 5'-end and a terminator region from a gene of interest at its 3'-end, is mutagenized and then introduced into P. rhodozyma. By detecting the difference of the activity of the reporter gene, an effective mutation would be screened. Such a mutation can be introduced in the sequence of the native promoter region on the chromosome by the same method as the case of an in vivo mutation approach. As donor DNA, a gene coding for an enzyme which catalyzes the reaction from beta-carotene to astaxanthin could be introduced. A coding sequence which is identical to its native sequence, as well as its allelic variant, a sequence which has one or more amino acid additions, deletions and/or substitutions as far as its corresponding enzyme has the same type of enzyme activity, can be used. Such a vector can then be introduced into P. rhodozyma by transformation and the transformants can be selected by spreading the transformed cells on an appropriate selection medium such as YPD agar medium containing geneticin in the case of pGB-Ph9 or a minimal agar medium omitting cytidine in the case of using auxotroph ATCC24221 as a recipient. Such a genetically engineered P. rhodozyma can be cultivated in an appropriate medium and evaluated for its productivity of astaxanthin. A hyper producer of astaxanthin thus selected would be confirmed in view of the relationship between its productivity and the level of gene or protein expression which is introduced by such a genetic engineering method. Examples The following materials and methods were employed in the specific Examples described below: Strains: P. rhodozyma ATCC96594 (This strain has been redeposited on April 8, 1998 as a Budapest Treaty deposit under accession No. 74438) P. rhodozyma ATCC96815 (This strain has been redeposited on February 18, 1999 as a Budapest Treaty deposit under accession No. 74486) E. coli DH5alpha F, phi80d, lacZdeltaM15, delta(lacZYA-argF)U169, hsd (r K - , m K + ), recA1, endA1, deoR, thi-1, supE44, gyrA96, relA1 (Toyobo, Osaka, Japan) E. coli XL1-Blue MRF': delta(mcrA)183, delta(mcrCB-hsdSMR-mrr)173, endA1, supE44, thi-1, recA1, gyrA96, relA1, lac[F' proAB, lacI q ZdeltaM15, Tn10 (tet r )] (Stratagene, La Jolla, USA) E. coli SOLR: e14 - (mcrA), delta(mcrCB-hsdSMR-mrr)171, sbcC, recB, recJ, umuC :: Tn5(kan r ), uvrC, lac, gyrA96, relA1, thi-1, endA1, lambda R , [F' proAB, lacI q ZdeltaM15] Su-(nonsuppressing) (Stratagene) E.coli TOP10: F - , mcrA, delta(mrr-hsdRMS-mcrBC), phi80, delta(lacZ M15), delta(lacX74), recA1, deoR, araD139, (ara-leu)7697, galU, galK, rpsL(Str r ), endA1, nupG (Invitrogen, NV Leek, Netherlands) E. coli BL21 (DE3) (pLysS): dcm - , ompTr B - m B - , lon - lambda(DE3), pLysS (Stratagene) Vectors: pUC19 (Takara Shuzo, Otsu, Japan) lambdaZAPII (Stratagene) pCR2.1-TOPO (Invitrogen) pET11c (Stratagene) Media P. rhodozyma strain is maintained routinely in YPD medium (DIFCO, Detroit, USA). E. coli strain is maintained in LB medium (10 g Bacto-trypton, 5 g yeast extract (DIFCO) and 5 g NaCl per liter). When an agar medium was prepared, 1.5 % of agar (WAKO, Osaka, Japan) was supplemented. Methods General molecular biology methods were done according to those described in Molecular cloning: a Laboratory Manual, 2nd Edition (Cold Spring Harbor Laboratory Press, 1989). Restriction enzymes and T4 DNA ligase were purchased from Takara Shuzo. Isolation of chromosomal DNA from P. rhodozyma was performed by using QIAGEN Genomic Kit (QIAGEN, Hilden, Germany) following the protocol supplied by the manufacturer. Mini-prep of plasmid DNA from transformed E. coli was performed with the Automatic DNA isolation system (PI-50, Kurabo, Co. Ltd., Osaka, Japan). Midi-prep of plasmid DNA from an E. coli transformant was performed by using QIAGEN column (QIAGEN). A DNA fragment was isolated and purified from agarose by using QIAquick or QIAEX II (QIAGEN). Fluorescent DNA primers for DNA sequencing were purchased from Pharmacia. DNA sequencing was performed with the automated fluorescent DNA sequencer (ALFred, Pharmacia, Uppsala, Sweden). Competent cells of DH5alpha were purchased from Toyobo. The apparatus and reagent for biolistic transformation of P. rhodozyma were purchased from Nippon Bio-Rad Laboratories (Tokyo, Japan). Example 1 Isolation of genomic DNA from P. rhodozyma To isolate a genomic DNA from P. rhodozyma, ATCC96594 the QIAGEN genomic kit was used according to the method specified by the manufacturer. At first, cells of P. rhodozyma ATCC96594 from 100 ml of overnight culture in YPD medium were harvested by centrifugation (1500 x g for 10 min.) and washed once with TE buffer (10 mM Tris / HCl (pH 8.0) containing 1 mM EDTA). After suspending in 8 ml of Y1 buffer of the QIAGEN genomic kit, lyticase (SIGMA, St. Louis, USA) was added at the concentration of 2 mg/ml to disrupt cells by enzymatic degradation and the reaction mixture was incubated for 90 minutes at 30 °C and then proceeded to the next extraction step. Finally, 20 µg of genomic DNA was obtained. Example 2 Construction of a genomic library from P. rhodozyma ATCC96594 As described in the section "detailed description of the invention", a plasmid harboring a drug resistant marker cassette was constructed by inserting a G418 resistant structure gene between the promoter and terminator region of the gene of the glyceraldehyde-3-phosphate dehydrogenase (GAP) and ligating this cassette into the KpnI- and HindIII-digested pUC19. This plasmid was named pUC-G418 and used further on. Then, a ClaI linker was ligated into the unique EcoRI site of the pUC-G418 vector and the resultant plasmid pUC-G418C1512 was obtained and used as a vector backbone in the construction of the Phaffia's genomic library. Then, 10 µg of chromosomal DNA prepared from P. rhodozyma ATCC96594 as described above in Example 1 was digested partially with 1.6 units of HpaII for 45 minutes at 37 °C and was subjected to agarose gel electrophoresis. After staining by ethidium bromide, partially digested DNA species from 4 to 10 kb were recovered by electroelution using a dialysis membrane. After ethanol precipitation of recovered HpaII fragments, 1.215 µg of DNA was obtained. Next, 3 µg of pG418C1512 was digested by 10 units of ClaI for an hour at 37 °C and precipitated with ethanol. ClaI-digested pG418C1512 was then dephosphorylated using calf intestine alkaline phosphatase. ClaI-digested and dephosphorylated pG418C1512 vector was then subjected to agarose gel electrophoresis and the DNA fragment was recovered using the QIAquick protocol according to the instructions of the manufacturer. Finally, 2.62 µg of ClaI-digested and dephosphorylated pG418C1512 was obtained. 2.62 µg of ClaI-digested and dephosphorylated pG418C1512 was ligated to 1.22 µg of HpaII-partially digested Phaffia's genomic DNA over night at 16 °C and the resultant ligation solution was used as donor DNA for the transformation of an E. coli DH5alpha strain. The total ligation mixture (270 µl) was transferred to 1 ml of competent cells of DH5a (Toyobo). After a heat shock treatment at 42 °C for 45 seconds succeeding by maintenance on ice for 30 minutes, the transformed cells were placed on ice for 2 minutes and then incubated at 37 °C for an hour with the addition of 5 ml of SOC medium: 0.5% yeast extract (DIFCO) 2% trypton (DIFCO) 10mM NaCl 2.5 mM KCl 10 mM MgCl 2 20 mM MgSO 4 20 mM glucose. Thus incubated cells were transferred into 100 ml of LB medium containing 100 gamma/ml of ampicillin. Cultivation was continued overnight at 37 °C and then the cells were harvested for plasmid midi-preparation. A plasmid library was prepared from harvested cells using QIAGEN midi-prep columns according to the method supplied by the manufacturer. Finally, 0.3 mg/ml of Phaffia's genomic library was obtained in the total volume of 5 ml and used as a genomic library in the further study. Example 3 Transformation of P. rhodozyma ATCC96815 with a biolistic method Transformation was done according to the method described in Methods in Molecular Biology (Johnston et al., 53; 147-153, 1996). As a host strain, P. rhodozyma ATCC96815 was cultured in YPD medium to the stationary phase. After centrifugation of the broth, cells were concentrated 10-fold with sterilized water and 200 µl of the cell suspension was spread on YPD medium containing 100 gamma/ml of geneticin, and 0.75 M of mannitol and sorbitol. Five micrograms of a genomic library, prepared as described in Example 2, was coated on 1.5 mg of 0.9 µm gold particle, and used as donor DNA for the biolistic transformation. Approximately twenty thousands of geneticin-resistant clones were yielded (300 to 500 colonies per plate) after one week of incubation at 20 °C. Although most of the transformants showed a yellow color (as the host strain, ATCC96815 did), three colonies pigmented red and were used further on. Example 4 Analysis of carotenoid obtained from red-pigmented transformants Red-pigmented transformants obtained from P. rhodozyma ATCC96815 were cultivated in 10 ml of YPD medium at 20 °C in test tubes. Then, cells were harvested from 0.5 ml of broth and used for the extraction of carotenoids from cells. The carotenoid content of P. rhodozyma was measured by HPLC after extraction of the carotenoids from cells of P. rhodozyma by disruption with glass beads as described. After extraction, disrupted cells were then collected by centrifugation and the resultant supernatant was analyzed for carotenoid content with HPLC. HPLC column; Chrompack Lichrosorb si-60 (4.6 mm, 250 mm) Temperature; room temperature Eluent; acetone / hexane (18 / 82) add 1 ml / L of water to elluent Injection volume; 10 µl Flow Rate; 2.0 ml/minute Detection; UV at 450 nm A sample of beta-carotene was purchased from SIGMA and astaxanthin was obtained from Hoffman La-Roche (Basel, Switzerland). As a result of HPLC analysis, it was confirmed that all three red transformants produced astaxanthin specifically though the host strain, ATCC96815 produced only beta-carotene. Example 5 Plasmid rescue from the chromosome of red transformants which produced astaxanthin Chromosomal DNA was prepared from all the astaxanthin-producing transformants. For this purpose, the QIAGEN genomic kit was used according to the method specified by the manufacturer, as described in Example 1. 5 µg of chromosomal DNA, thus prepared, was digested by HindIII and then purified according the QIAquick protocol. E. coli DH5alpha competent cells were transformed by the ligated DNA solutions and then spread on LB agar medium containing 100 µg/ml of ampicillin. All of the transformants had the same insert fragments in their plasmids, judging from sequence analysis of the plasmids. This indicated that three independent red transformants derived from P. rhodozyma ATCC96815 were yielded by the same type of recombination event between the donor DNA of the genomic library and chromosomal DNA. One of the plasmids thus rescued was named pR2-4 and used further on. Example 6 Screening of the original genomic library by using pR2-4 as a hybridization probe Because the rescued fragment in pR2-4 may have mutations depending on the direction of the recombination event yielding red transformants of P. rhodozyma, screening of the original genomic library was done by using pR2-4 as a hybridization probe. For this purpose, twenty thousand E. coli transformants of the original genomic library, as described in Example 2 were transferred to nylon membrane filters (Hybond-N+, Amersham, Buckinghamshire, UK) and subjected to colony hybridization. Three transformants which harbored the same nucleotide sequence in their insert as that of pR2-4 were isolated. The isolated plasmids from these transformants were named pR3, pR5.1 and pR16. Next, P. rhodozyma ATCC96815 was transformed by pR3, pR5.1 and pR16. All the transfomants colored red. This result suggests that the isolated plasmids might contain the gene encoding an enzyme involved in the reaction of beta-carotene to astaxanthin in P. rhodozyma. We designated this gene as AST gene. Among these plasmids, pR16 was used further on. Example 7 Isolation of mRNA from P. rhodozyma for cDNA analysis To analyze the pattern of transcripts from P. rhodozyma, total RNA was isolated from P. rhodozyma ATCC96594 and ATCC96815 by phenol extraction by combination of the cell disruption with glass beads and purified mRNA using an mRNA separation kit (Clontech, Palo Alto, USA). At first, cells of ATCC96594 and ATCC96815 strains from 10 ml of a two-day-culture in YPD medium were harvested by centrifugation (1500 x g for 10 min.) and washed once with extraction buffer (100 mM Tris / HCl (pH 7.5) containing 0.1 M LiCl and 0.1 mM EDTA). After filling up to 5.0 ml of cell suspension with the same extraction buffer in 50 ml disposable centrifuge tube (IWAKI Glass, Tokyo, Japan), 1.5 ml of isogen-LS (Nippon gene, Toyama, Japan) and 10 grams of glass beads were added. Centrifuge tubes which contained the cell suspension with isogen-LS and glass beads was shaken with a horizontal table top shaker for an hour. In this step, 300 µg of total RNA was recovered. Then, mRNA was purified by using an mRNA separation kit (Clontech). On 8.0 µg of mRNA from P. rhodozyma ATCC96594 and ATCC96815 strains were obtained. To synthesize cDNA, we used the SMART cDNA construction kit (Clontech) according to the method specified by the manufacturer. We applied 2 µg of purified mRNA for a first strand synthesis followed by PCR amplification and obtained 1 mg of cDNA. Example 8 Subcloning of pR16 and functional analysis of its insert fragment The restriction map of pR16 is depicted in FIG. 2. Each EcoRI fragment whose length was 0.7 and 2.7 kb, was subcloned into pUC-G418 and named pRS913 and pRLR913, respectively. Then, the astaxanthin-producing P. rhodozyma ATCC96594 strain was transformed with pRS913. As a result of this transformation study, yellow transformants were yielded. This suggested that 0.7 kb EcoRI fragment might contain a truncated AST gene and the transformation via a single-cross recombination between a 0.7 kb EcoRI fragment and its homologous sequence on the choromosome of P. rhodozyma would result in a gene disruption of the AST gene on the choromosome of P. rhodozyma. Next, the beta-carotene-producing ATCC96815 strain was transformed with pRLR913 and red transformants were yielded. This suggested that the mutation point of strain ATCC96815 which led the astaxanthin-producing wild type strain to produce beta-carotene would lie in the 2.7 kb EcoRI fragment originally adjacent to the 0.7 kb EcoRI fragment in pR16. Two hundred µg of cDNA prepared in Example 7 was subjected to agarose gel electrophoresis for virtual Northern analysis. In the case of the cDNAs prepared from ATCC96594 and 96815, two bands which, namely at 3.2 and 2.0 kb were hybridized in both cases by using the 2.7 kb EcoRI fragment of pRLR913 as a hybridization probe. This suggested that the ast mutation of ATCC96815 would be a point mutation which did not reflect to the change of the length of mRNA such as missense mutation. In the case of using the 0.7 kb EcoRI fragment of pRS913 as a hybridization probe, a band of 2.0 kb was hybridized. From this study, it seemed that the AST gene might give a 2.0 kb transcript in P. rhodozyma. Example 9 Cloning of the cDNA of the AST gene To clone the cDNA for the AST gene from P. rhodozyma, we constructed cDNA library from P. rhodozyma ATCC96594. Total RNA was isolated by phenol extraction by combination of the cell disruption with glass beads as described in Example 7. At first, cells of the ATCC96594 strain from 50 ml of a two-day-culture in YPD medium were harvested by centrifugation (1500 x g for 10 min.) and washed once with extraction buffer (100 mM Tris / HCl (pH 7.5) containing 0.1 M LiCl and 0.1 mM EDTA). After filling up to 5.0 ml of cell suspension with the same extraction buffer in 50 ml disposable centrifuge tube (IWAKI Glass), 1.5 ml of isogen-LS (Nippon gene) and 10 grams of glass beads were added. Centrifuge tubes which contained cell suspension with isogen-LS and glass beads were shaken with a horizontal table top shaker for an hour. In this step, 1.8 mg of total RNA was recovered. Then, mRNA was purified by using the PolyATtract mRNA isolation system (Promega corp., Madison, USA) according to the method specified by the manufacturer. Finally, we obtained 8.0 µg of mRNA from the P. rhodozyma ATCC96594 strain. To construct a cDNA library, 8.0 µg of the purified mRNA was used in the COPY kit (Invitrogen, Carlsbad, USA) with the protocol specified by the manufacturer. After ligation of a EcoRI adaptor (Stratagene), synthesized cDNA was subjected to agarose gel electrophoresis. After the excision of the agarose gel piece which covered the length of cDNAs from 1.9 to 2.3 kb, the collected cDNA species were purified by QIAEX II (QIAGEN). This size-fractionated cDNA was ligated to EcoRI-digested and dephosphorylated lambdaZAPII (Stratagene). The over-night ligation mixture was in vitro packaged with Gigapack III gold extract (Stratagene) and used for infection to E. coli XL1-Blue MRF' strain. Conventional plaque screening was performed against 6000 plaques using 2.7 and 0.7 kb EcoRI fragment as described in Example 8 as hybridization probes. One plaque hybridized strongly to these probes, picked up with a sterilized toothpick and the eluted phage particle were used for in vivo excision, according to the method specified by the manufacturer. Finally, infected transformants of E. coli SOLR cells which showed resistance against ampicillin were isolated. After sequencing of the isolated plasmids obtained from these transformants, it turned out that these plasmids contained the same fragment as a part of the sequence of pR16 which was described in Example 6. The entire sequence of the cDNA of the AST gene was determined and is shown as SEQ ID NO: 2 and its deduced amino acid sequence as SEQ ID NO: 1. Example 10 In vitro characterization of the AST gene product For the enzymatic characterization of the AST gene product, a standard assay which is used for the characterization of P450 enzymes can be applied. For this purpose, it is necessary that the reaction mixture contains a reconstituted membrane. As a reconstituted membrane, natural isolates such as mitochondrial membranes or microsomes and artificial membranes are often used. In any cases, it is necessary that an electron transfer between an electron acceptor and a receptor can occur. As an electron donor, cytochrome P450 reductase is often added to the reaction mixture. As an electron acceptor, oxygen molecules are involved. Under the presence of an electron source, such as reduced NADPH+, beta-carotene, which is a substrate of astaxanthin synthase can be converted to astaxanthin. Produced astaxanthin can be assayed qualitatively and quantitatively with HPLC analysis. Example 11 Cloning of genomic fragment containing AST gene To determine the genomic sequence containing the AST gene, a sequencing experiment was performed by using primer-walking procedure. Sequencing analysis of pRS913 showed that pRS913 did not contain the 3' end of AST gene. To obtain the 3'-adjacent genomic fragment to AST gene, genome-walking experiment was performed. To do this, universal genome walker kit (Clontech) was exploited according to the method specified by the manufacturer. As a template of PCR, chromosomal DNA prepared in Example 1 was used. Gene specific primer, ast15 whose sequence was as listed in TABLE 1 was synthesized and used for PCR primer; TABLE 1 Sequence of primer used for genome walking of AST gene PCR fragments which had appropriate length (smaller than 1 kb) were obtained from EcoRV and StuI library, purified and cloned into pCR2.1-TOPO (Invitrogen). As a result of sequencing, it was found that both fragments contained the genomic fragment contained AST gene. Based on the sequence which was located at 200 bp from polyA site for AST gene, PCR primer was designed as listed in TABLE 2. TABLE 2 Sequence of primer for cloning of 3'-adjacent fragment to AST gene By using ast15 and ast18 primers as PCR primers and chromosomal DNA prepared in Example 1 as PCR template, PCR was conducted. Proof-reading polymerase (HF polymerase, Clontech) ensured the amplification of PCR fragment which had exact sequence. PCR condition was as follows; 25 cycles of 15 seconds at 94 °C, 30 seconds at 55 °C and 30 seconds at 72 °C. Six independent clones which had 400 bp inserts showed the identical sequence. By combined with sequences for pRS913 and pRL913, 3.9 kb sequence containing AST gene containing 474 bp of promoter region and 269 bp of terminator region was determined (SEQ ID NO. 3). As a result, AST gene showed intron-rich structure (17 introns). Example 12 Determination of mutation point in beta-carotene producing strain, P. rhodozyma ATCC96815 To confirm the fact that beta-carotene production by P. rhodozyma ATCC96815 strain was caused from the mutation within the AST gene, genomic sequence containing AST gene obtained from ATCC96815 and its parent strain P. rhodozyma ATCC24230 were determined. To do this, PCR primers whose sequences were as listed in TABLE 3 were synthesized and used for PCR cloning; TABLE 3 PCR primers for cloning entire genomic AST gene; By using HF polymerase (Clontech) as PCR polymerase and chromosomal DNA prepared from strains, ATCC96815 and ATCC24230 by the same protocol as Example 1 as PCR template, PCR was performed under the condition as follows; 25 cycles of 15 seconds at 94 °C, 30 seconds at 55 °C and 4 minutes at 72 °C. PCR fragments obtained whose length were approximate 3.5 kb were cloned into pCR2.1-TOPO and sequenced for their entire sequences by primer walking procedure. Between the sequence for P. rhodozyma ATCC96594 strain and ATCC24230 strain, 7 base changes were found. Four base changes were found in its exon sequence but those did not give any amino acid changes. Three base changes were found in its intron structure. In comparison between beta-carotene producing strain ATCC96815 and its parent strain, ATCC24230, one base change which was located at 5'-splicing sequence (GTAAGT > GTAAAT) within the eighth intron was found. This might indicate that mutation which conferred the phenotype of beta-carotene accumulation on astaxanthin-producing P. rhodozyma was caused from improper splicing of mRNA for AST gene. To confirm this assumption, RT-PCR was performed by using cDNA prepared from P. rhodozyma ATCC96815 as PCR template. mRNA was isolated from P. rhodozyma ATCC96815 by the same protocol as Example 9 and used for the synthesis of cDNA. To obtain cDNA from this mRNA prepared from ATCC96815 by PCR method, SMART PCR cDNA library construction kit (Clontech) was exploited according to the method specified by supplier. The following primers whose sequence were as listed in TABLE 4 and which covered eighth intron were synthesized and used for PCR primers. TABLE 4 PCR primers for RT-PCR to detect the improper splicing product for AST gene RT-PCR condition was as follows; 25 cycles of 15 seconds at 94 °C, 30 seconds at 55 °C and 30 seconds at 72 °C. As a result of PCR, 300 bp of PCR products were amplified and cloned into pCR2.1-TOPO. Two independent clones which had 300 bp insert were sequenced. As a result, it was confirmed that improper splicing products for AST gene was synthesized in the P. rhodozyma ATCC96815 strain. Improper splicing for the eigth intron of AST gene might cause the production of shorter truncated AST protein than AST protein spliced properly because stop codon lay in the eighth intron. This result indicated that mutation point lay in AST gene which failed in the proper splicing. Example 13 Flask fermentation by recombinants in which recombinant AST gene was integrated on the chromosome of beta-carotene-producing P. rhodozyma The productivity of astaxanthin was evaluated in the flask fermentation. The medium formulation for flask fermentation is as follows. Seed medium formulation for flask fermentation Glucose 30.0 g / l NH 4 Cl 4.83 g / l KH 2 PO 4 1.0 / l MgSO 4 -7H 2 O 0.88 g / l NaCl 0.06 g / l CaCl 2 -2H 2 O 0.2 g / l KH phthalate 20.0 g / l FeSO 4 -7H 2 O 28 mg / l Citric acid-1H 2 O 15.0 mg / l ZnSO 4 -7H 2 O 40.0 mg / l CuSO 4 -5H 2 O 0.75 mg / l MnSO4-4,5H 2 O 0.6 mg / l H 3 BO 3 0.6 mg / l Na 2 MoO 4 -2H 2 O 0.6 mg / l KI 0.15 mg / l Myo-inositol 60.0 mg / l Nicotinic acid 3.0 mg / l Ca D-pantothenate 3.0 mg / l Vitamin B1 (thiamin HCl) 3.0 mg / l p-Aminobenzoic acid 1.8 mg / l Vitamin B6 (pyridoxine HCl) 0.3 mg / l Biotin 0.048 mg / l 7 ml / Test Tube (21 mm diameter) Medium formulation for flask fermentation MgSO 4 -7H 2 O 2.1 g / l CaCl 2 -2H 2 O 0.865 g / l (NH 4 ) 2 SO 4 3.7 g / l FeSO 4 -7H 2 O 0.28 g / l Glucose (sterilized separately) 22 g / l KH 2 PO 4 (sterilized separately) 14.25 g / l Citric acid-1H 2 O 0.21 g / l ZnSO 4 -7H 2 O 70.14 mg / l CuSO 4 -5H 2 O 10.5 mg / l MnSO 4 -4,5H 2 O 8.4 mg / l H 3 BO 3 8.4 mg / l Na 2 MoO 4 -2H 2 O 8.4 mg / l KI 2.1 mg / l Myo-inositol 0.374 g / l Nicotinic acid 18.7 mg / l Ca D-pantothenate 28.05 mg / l Vitamin B1 (thiamin HCl) 18.7 mg / l p-Aminobenzoic acid 11.22 mg / l Vitamin B6 (pyridoxine HCl) 1.87 mg / l Biotin 1.122 mg / CaCO3 10 g / l 1 drop of Actcol (Takeda Chemical Industries Ltd., Osaka, JAPAN) was added to each flask. 50ml (final volume with 5% of seed inoculum) 500 ml flask with buffles Cells were harvested from fermented broth after 7-day fermentation and analyzed for their accumulation of astaxanthin and beta-carotene by HPLC as described in Example 4. Results are summarized in TABLE 7. Restoration of astaxanthin production by the recombinants in which AST gene was integrated. (Data is indicated as relative titer of astaxanthin and beta-carotene against the titer of beta-carotene accumulated by P. rhodozyma ATCC96815) Relative titer (%) Strain Astaxanthin Beta-carotene ATCC96815 :: pR16 34.0 % 18.6 % ATCC96815 0 % 100 % SEQUENCE LISTING <110> F. HOFFMANN-LA ROCHE. AG <120> Improvement of astaxanthin production and biological material therefor <130> P450ast <140> <141> <160> 32 <170> PatentIn Ver. 2.0 <210> 1 <211> 557 <212> PRT <213> Phaffia rhodozyma <220> <221> TRANSIT <222> (1)..(26) <400> 1 <210> 2 <211> 1932 <212> DNA <213> Phaffia rhodozyma <220> <221> CDS <222> (33)..(1706) <220> <221> polyA_site <222> (1871) <220> <221> mRNA <222> (14)..(1891) <400> 2 <210> 3 <211> 3969 <212> DNA <213> Phaffia rhodozyma <220> <221> 5'UTR <222> (517)..(518) <223> EXPERIMENTAL <220> <221> exon <222> (535)..(652) <220> <221> intron <222> (653)..(734) <220> <221> exon <222> (735)..(783) <220> <221> intron <222> (784)..(898) <220> <221> exon <222> (899)..(1015) <220> <221> intron <222> (1016)..(1087) <220> <221> exon <222> (1088)..(1179) <220> <221> intron <222> (1180)..(1302) <220> <221> exon <222> (1303)..(1517) <220> <221> intron <222> (1518)..(1600) <220> <221> exon <222> (1601)..(1634) <220> <221> intron <222> (1635)..(1723) <220> <221> exon <222> (1724)..(1866) <220> <221> intron <222> (1867)..(1939) <220> <221> exon <222> (1940)..(1999) <220> <221> intron <222> (2000)..(2081) <220> <221> exon <222> (2082)..(2181) <220> <221> intron <222> (2182)..(2257) <220> <221> exon <222> (2258)..(2354) <220> <221> intron <222> (2355)..(2431) <220> <221> exon <222> (2432)..(2542) <220> <221> intron <222> (2543)..(2618) <220> <221> exon <222> (2619)..(2652) <220> <221> intron <222> (2653)..(2742) <220> <221> exon <222> (2743)..(2814) <220> <221> intron <222> (2815)..(2962) <220> <221> exon <222> (2963)..(3050) <220> <221> intron <222> (3051)..(3113) <220> <221> exon <222> (3114)..(3171) <220> <221> intron <222> (3172)..(3247) <220> <221> exon <222> (3248)..(3321) <220> <221> intron <222> (3322)..(3398) <220> <221> exon <222> (3399)..(3423) <220> <221> intron <222> (3424)..(3513) <220> <221> exon <222> (3514)..(3700) <220> <221> polyA_site <222> (3865)..(3866) <223> EXPERIMENTAL <400> 4 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: sense primer for expression of AST gene in E. coli <400> 4 <210> 5 <211> 47 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: antisense primer for expression of AST gene in E. coli <400> 5 <210> 6 <211> 45 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: 5' sense primer for expression of modified AST gene in E. coli <400> 6 <210> 7 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: 5' antisense primer for expression of modified AST gene in E. coli <400> 7 <210> 8 <211> 26 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: 3' antisense primer for expression of modified AST gene in E. coli <400> 8 <210> 9 <211> 26 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: genome walking primer for cloning of AST gene <400> 9 <210> 10 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: antisense primer for cloning of terminator region of AST gene <400> 10 <210> 11 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: sense primer for cloning genomic AST gene <400> 11 <210> 12 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: antisense primer for cloning genomic AST gene <400> 12 <210> 13 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: sense primer for RT-PCR of AST gene <400> 13 <210> 14 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: antisense primer for RT-PCR of AST gene <400> 14

Claims: An isolated DNA comprising a nucleotide sequence coding for an enzyme having astaxanthin synthase activity catalyzing the reaction from beta-carotene to astaxanthin, characterized in that said nucleotide sequence is selected from the nucleotide sequences represented in SEQ ID NO:2 and SEQ ID NO:3. The isolated DNA of claim 1, characterized in that said nucleotide sequence is: (a) a nucleotide sequence which, because of the degeneracy of the genetic code, encodes an astaxanthin synthase having the same amino acid sequence as that encoded by the nucleotide sequences as shown in SEQ ID NO:2 and SEQ ID NO:3; (b) a nucleotide sequence which hybridizes to the complement of the nucleotide sequences of SEQ ID NO:2 and SEQ ID NO:3 coding for an astaxanthin synthase under the medium stringent hybridizing conditions 50% (V/V) formamide, 5 x SSC, 2% (W/V) blocking reagent, 0.1% (W/V) N-lauroylsarcosine and 0.3% (W/V) SDS at a temperature of 42°C over night. A vector or plasmid comprising the isolated DNA as claimed in claims 1 or 2. A host cell transformed or transfected by the isolated DNA as claimed in claims 1 or 2 or a vector or plasmid as claimed in claim 3. A polypeptide encoded by the isolated DNA as claimed in anyone of claims 1 to 4. A process for the production of a polypeptide having an activity of astaxanthin synthase which comprises culturing a transformed host cell as claimed in claim 4 under the conditions conductive to the production of said enzyme. A process for the biological production of astaxanthin which comprises introducing one or more isolated DNAs as claimed in claims 1 or 2 into an appropriate host organism, cultivating the obtained organism under the condition conductive to the production of astaxanthin and recovering astaxanthin from the culture. A process for the production of astaxanthin said process comprises contacting beta-carotene with a polypeptide being encoded by the nucleotide sequences as shown in SEQ ID NO:2 and SEQ ID NO:3 and having an activity of astaxanthin synthase in the presence of an electron donor, like the cytochrome P450 reductase, which can reduce the polypeptide's reaction center in a reaction mixture containing the polypeptide in form of a reconstituted membrane which is prepared from a biological membrane like a microsome or a mitochondrial membrane or wherein the polypeptide is present in the form of a reconstituted artificial membrane, like a liposome.

Inventors: HOSHINO TATSUO, OJIMA KAZUYUKI, SETOGUCHI YUTAKA, HOSHINO, TATSUO, OJIMA, KAZUYUKI, SETOGUCHI, YUTAKA
Applicants: HOFFMANN LA ROCHE, F. HOFFMANN-LA ROCHE AG
Application year: 2000
Main classification: C12N15
IPC codes: C12P23, C12N9